CAR T Cell Therapy Related Cardiovascular Outcomes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-18

Study Completion Date

2023-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This will be a cohort study of all patients receiving Cluster of Differentiation 19 (CD19)-specific CAR T cell therapy for relapsed/refractory B cell haematological malignancies. Patients will receive cardiac assessment and have serum cardiac biomarkers, ECG, transthoracic echocardiogram and cardiac magnetic resonance imaging performed at baseline prior to CAR T cell therapy, 7 days post CAR T cell infusion, and 3 months post CAR T cell infusion. Abnormalities in these cardiac investigations will be used to demonstrate cardiac injury and identify which patients are most at risk of developing cardiac injury related to CAR T cell therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Assessment of Cardiac Function After Treatment With CAR-T Cells

NCT06350994

Car T- Cell Hematologic Malignancy Acute Lymphoblastic Leukemia +2 more

RECRUITING

A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies

NCT07316907

Hematologic Malignancies Lymphoma

NOT_YET_RECRUITING PHASE1

Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma

NCT04833504

Diffuse Large B-cell Lymphoma Mantle Cell Lymphoma Transformed Follicular Lymphoma +1 more

COMPLETED

Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells

NCT05675982

Diffuse Large B Cell Lymphoma

ACTIVE_NOT_RECRUITING NA

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19

NCT01864889

Hematopoietic/Lymphoid Cancer Adult Acute Lymphoblastic Leukemia in Remission B-cell Adult Acute Lymphoblastic Leukemia +20 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

CD19-specific chimeric antigen receptor (CAR) T cells are a novel therapy for relapsing or refractory blood cancers, which have delivered a significant improvement in the rates of complete and partial remission. However, they are associated with toxicities, with some of early evidence suggestive of cardiovascular involvement. Despite this, the full extent of cardiovascular toxicity is poorly understood.

This research study seeks to understand the cardiac safety of CAR T cells in patients who receive this therapy as part of standard care for relapsed/refractory B-cell blood cancer. They will be assessed for cardiovascular risk factors via history, blood biomarkers, and cardiac imaging tests. These parameters will be repeated at 7 days following administration of the CAR T cells or if there are signs of cardiovascular deterioration, and again at 3 months follow up.

The aim is to predict the cohort most at risk of cardiovascular toxicity, and demonstrate evidence of cardiac injury on the cardiac imaging scans.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Diseases B-cell Acute Lymphoblastic Leukemia B-cell Lymphoma Refractory B-cell Lymphoma Recurrent Primary Mediastinal Large B-cell Lymphoma (PMBCL) Diffuse Large B Cell Lymphoma Cardiotoxicity Cardiovascular Complication